BRAF and lung carcinoma: To study these protein interactions under RAF inhibitor treatment, we performed immunoprecipitation (IP)-western blot analysis examining endogenous ARAF, BRAF, and CRAF protein complexes in three patient-derived lung cancer cell lines, each representing a different BRAF mutation class: HCC364 (Class I; BRAF V600E), NCI-H2405 (Class II; BRAF L485_P490delinsY), and NCI-H1666 (Class III; BRAF G466V).